Arisaph Pharmaceuticals Inc

Quick facts

Phase 2 pipeline

• ARI-3037MO · Diabetes
  ARI-3037MO is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arisaph Pharmaceuticals Inc portfolio CI brief
• Arisaph Pharmaceuticals Inc pipeline updates RSS